Tell us about your biggest trial win from January 2016 to July 2017 and how you achieved the result for your client.

From the client's perspective, all trials are the “biggest,” and our team approaches every matter that way. For the legal community, the In re Modafinil trial is perhaps most interesting, as this was only the second “reverse payment” case to go to trial since the Actavis decision (my team also tried the first one, In re Nexium).

The case was significant because claimed damages were in the billions, the law remains uncertain and the legal substance involved complex overlap between antitrust and patent laws.